We believe that this is the key point in EGF+61A/G polymorphism research within the lung cancer context. First, determine whether EGF+61A/G polymorphisms with NSCLC susceptibility are present. Second, test their influence on patient outcomes and assess whether they could serve both as risk markers and as predictive biomarkers. Finally, assess their role in cancer prevention, perhaps in correlations with other risk factors and as contributions towards creating nomograms in order to predict cancer risk. This could help in future public preventive healthcare strategies, but great effort is still required in order to validate these issues in other populations.
